Horizon Pharma PLC’s (HZNP) “Hold” Rating Reaffirmed at Mizuho
Horizon Pharma PLC (NASDAQ:HZNP)‘s stock had its “hold” rating restated by equities research analysts at Mizuho in a note issued to investors on Monday. They presently have a $12.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $9.00. Mizuho’s target price would suggest a potential downside of 10.65% from the company’s previous close.
A number of other analysts have also recently weighed in on HZNP. BMO Capital Markets reiterated a “buy” rating and set a $17.00 price target (down previously from $24.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Cowen and Company set a $20.00 price target on shares of Horizon Pharma PLC and gave the stock an “outperform” rating in a research note on Tuesday, May 9th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price target (down previously from $35.00) on shares of Horizon Pharma PLC in a research note on Tuesday, May 9th. Jefferies Group LLC set a $14.00 price target on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Finally, Citigroup Inc. decreased their price target on shares of Horizon Pharma PLC from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Horizon Pharma PLC has a consensus rating of “Buy” and a consensus target price of $19.69.
Horizon Pharma PLC (HZNP) traded down 0.30% on Monday, hitting $13.39. The company’s stock had a trading volume of 1,272,772 shares. The firm has a 50 day moving average of $12.66 and a 200 day moving average of $13.40. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The firm’s market cap is $2.19 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million during the quarter, compared to analysts’ expectations of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.56 EPS. Equities research analysts forecast that Horizon Pharma PLC will post $1.09 earnings per share for the current fiscal year.
Horizon Pharma PLC announced that its board has approved a stock buyback program on Monday, May 8th that permits the company to repurchase 1,000% of shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: “Horizon Pharma PLC’s (HZNP) “Hold” Rating Reaffirmed at Mizuho” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/horizon-pharma-plcs-hznp-neutral-rating-reiterated-at-mizuho/1527770.html.
Several hedge funds have recently added to or reduced their stakes in HZNP. Bank of Montreal Can boosted its stake in Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,378 shares during the period. Sheaff Brock Investment Advisors LLC boosted its stake in Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 500 shares during the period. Family Management Corp purchased a new stake in Horizon Pharma PLC during the second quarter valued at approximately $131,000. Ballentine Partners LLC purchased a new stake in Horizon Pharma PLC during the second quarter valued at approximately $139,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in Horizon Pharma PLC during the first quarter valued at approximately $151,000. Institutional investors own 82.30% of the company’s stock.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.